Tag: lexicon pharmaceuticals

December 3, 2019

Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC

The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical...
September 22, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Lexicon Soars

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
August 11, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Paratek Up 41 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
March 15, 2019

Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced the dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract Cancer...
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.
December 20, 2018

Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes

Lexicon Pharmaceuticals (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1...
November 29, 2018

FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes

Lexicon Pharmaceuticals (Nasdaq:LXRX), today announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) plans...